Inventor · disambiguated record
Adam Zwolak
Also filed as: ZWOLAK ADAM
9 granted patents·18 pending applications·12 citations·filing 2015–2025
79Inventor score
Top patents by PatentIndex Score
27 records- 0191US12084501B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2022·Granted Sep 10, 2024·2 cites·44 claims
- 0291US11149094B2Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutationsJANSSEN BIOTECH INC·Filed 2018·Granted Oct 19, 2021·9 cites·41 claims
- 0384US12378326B2Anti-CD28 x anti-PSMA antibodiesXENCOR INC·Filed 2024·Granted Aug 5, 2025·0 cites·30 claims
- 0481US2025388704A1Anti-cd28 x anti-psma antibodiesXENCOR INC·Filed 2025·Application pending·0 cites
- 0579US12365743B2Anti-CD28 x anti-PSMA antibodiesXENCOR INC·Filed 2023·Granted Jul 22, 2025·0 cites·1 claims
- 0676US2023322961A1Anti-cd28 x anti-psma antibodiesXENCOR INC·Filed 2023·Application pending·0 cites
- 0775US2025145711A1Proteins comprising cd3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 0868US10865253B2Rodent bispecific heterodimeric proteinsGENMAB AS·Filed 2015·Granted Dec 15, 2020·1 cites·14 claims
- 0968US2025136688A1Stabilized cd3 antigen binding agents and methods of use thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1067US2025188163A1Gprc5d antibodies with enhanced effector function and uses thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1166US2025066510A1Gucy2c antibodies and uses thereofJANSSEN BIOTECH INC·Filed 2024·Application pending·0 cites
- 1263US2025122299A1ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIESXENCOR INC·Filed 2024·Application pending·0 cites
- 1361US2025136672A1Multispecific antibodies and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 1461US2025368756A1Enhanced protein compositionsJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1561US2025188181A1Multispecific antibodies and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 1661US2025129144A1Multispecific antibodies and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 1760US2025230254A1Biosynthetic bioparatopic or bispecific binding molecules with enhanced effector functionsJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 1860US2025011454A1Biosynthetic monovalent binding molecules with enhanced effector functionsJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
- 1959US12460001B2Proteins comprising CD3 antigen binding domains and uses thereofJANSSEN BIOTECH INC·Filed 2021·Granted Nov 4, 2025·0 cites·50 claims
- 2056US2024025992A1Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their usesJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2156US2024182582A1Materials and methods for immune effector cells redirectionJANSSEN BIOTHECH INC·Filed 2022·Application pending·0 cites
- 2255US2022324970A1Materials and methods for multidirectional biotransportationJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 2355US2023019640A1Materials and methods for polymeric antibody receptor targetingJANSSEN BIOTECH INC·Filed 2020·Application pending·0 cites
- 2451US11952411B2Materials and methods of using engineered ligandsJANSSEN BIOTECH INC·Filed 2021·Granted Apr 9, 2024·0 cites·18 claims
- 2551US2022356266A1Biosynthetic glycoprotein populationsJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2649US12134658B2Materials and methods for multidirectional biotransportation in virotherapeuticsJANSSEN BIOTECH INC·Filed 2021·Granted Nov 5, 2024·0 cites·18 claims
- 2747US11827708B2Proteins comprising HLA-G antigen binding domains and their usesJANSSEN BIOTECH INC·Filed 2021·Granted Nov 28, 2023·0 cites·28 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →